In patients with MS, the number of active CD4+ T cells correlates with disease severity; thus, inhibition of these cells may reduce disease signs, symptoms, and progression (Chitnis, 2007; Peeters et al., 2017). This evidence concerns the gene CD4 and myeloid sarcoma.